Illumina (ILMN) Stock Price
Illumina Price
Illumina (ILMN) Stock | ISIN US4523271090 | WKN 927079. The current Illumina stock price is 158.04 USD (2026). Revenue is 4.63 B USD. Net income is 807.63 M USD. The P/E ratio is 30.53. Market capitalization is 24.65 B USD. Illumina operates in the Health sector.
Illumina stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Illumina over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Illumina stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Illumina's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Illumina Price |
|---|
Illumina Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Illumina Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Illumina generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Illumina retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Illumina's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Illumina has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Illumina's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Illumina stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Illumina Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Illumina business model & stock analysis
Illumina SWOT Analysis
Strengths
Illumina Inc. is a leading provider of sequencing and array-based technologies for genetic analysis. The company's strengths include:
- Strong market position: Illumina holds a significant market share in the genetic sequencing and analysis industry, making it a leader in the field.
- Robust product portfolio: The company offers a wide range of innovative products and solutions, catering to diverse research and clinical applications.
- Advanced technology: Illumina's cutting-edge sequencing platforms and bioinformatics tools are known for their accuracy, speed, and scalability.
- Strong research and development capabilities: Illumina invests heavily in R&D, allowing it to continuously develop and launch new products to stay ahead of the competition.
Weaknesses
Despite its strengths, Illumina Inc. also faces certain weaknesses that could impede its growth and competitiveness:
- High product and service costs: Illumina's technologies and services can be expensive, limiting accessibility for some customers and hindering adoption in certain markets.
- Dependence on key customers: The company's revenues are heavily reliant on a few major customers, leaving it vulnerable to client-specific risks.
- Regulatory challenges: Illumina operates in a highly regulated industry, requiring compliance with various local and international regulations, which can limit its flexibility and increase operational costs.
- Limited geographic presence: Although Illumina has a global reach, its market penetration is not evenly distributed worldwide, leaving certain regions underrepresented.
Opportunities
To sustain its growth and expand its business, Illumina Inc. can capitalize on several opportunities:
- Increasing demand for genomic medicine: The growing understanding of genetics and personalized medicine presents a significant opportunity for Illumina to provide genetic testing and analysis services for healthcare purposes.
- Emerging markets: Illumina can focus on expanding its presence in developing countries where there is a rising demand for genetic analysis technologies, such as China and India.
- Partnerships and collaborations: Collaborating with research institutions, pharmaceutical companies, and other industry players can lead to new product development and mutual benefits.
- Technological advancements: Continuously improving its existing technologies, developing new sequencing methods, and exploring other genetic analysis techniques can open up new avenues for Illumina's growth.
Threats
Illumina Inc. faces certain threats that could impact its market position and profitability:
- Competition: The genetic sequencing and analysis market is highly competitive, with several established players as well as new entrants offering alternative technologies and solutions.
- Intellectual property disputes: Legal battles related to patents and intellectual property rights can divert resources, damage reputation, and hinder product development.
- Data privacy concerns: As genetic sequencing generates a vast amount of personal data, any data breaches or misuse can harm Illumina's reputation and lead to regulatory scrutiny.
- Technology obsolescence: Rapid advancements in the field of genetic analysis can render existing technologies obsolete, requiring continuous innovation and adaptation.
Illumina Segments
Illumina Revenue by Segment (1/5)
3 Years
Max
Details
Illumina Revenue by Segment (2/5)
3 Years
Max
Details
Illumina Revenue by Segment (3/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Illumina Revenue by Segment (4/5)
3 Years
Max
Details
Illumina Revenue by Segment (5/5)
Max
Details
Illumina Revenue by Region
3 Years
5 Years
Max
Details
Illumina Eulerpool Fair Value
Illumina historical P/E ratio, EBIT multiple, and P/S ratio
Illumina annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Illumina shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Illumina Earnings Estimates
Illumina Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 4/30/2026 | 1.08USD | 1.09 BUSD | 2026 Q1 |
| 4/28/2026 | 1.08USD | 1.09 BUSD | 2026 Q1 |
| 2/5/2026 | 1.25USD | 1.12 BUSD | 2025 Q4 |
| 11/7/2024 | 0.89USD | 1.1 BUSD | 2024 Q3 |
| 4/23/2024 | 0.09USD | 1.08 BUSD | 2024 Q1 |
| 2/5/2024 | -0.07USD | 1.09 BUSD | 2023 Q4 |
| 8/9/2023 | 0.63USD | 1.23 BUSD | 2023 Q2 |
| 5/3/2023 | 0.57USD | 1.17 BUSD | 2023 Q1 |
| 2/8/2023 | 0.46USD | 1.08 BUSD | 2022 Q4 |
| 11/3/2022 | 0.3USD | 1.13 BUSD | 2022 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Illumina stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Illumina shareholder structure
| % | Name |
|---|---|
10.67007% | |
9.6643% | |
8.72541% | |
3.60081% | |
3.02748% | |
2.83748% | |
2.70867% | |
2.45488% | |
2.11274% | |
1.89126% |
Illumina Executives and Management Board
Mr. Jacob Thaysen
(49)Chief Executive Officer, Director · since 2023
Mr. Everett Cunningham
(58)Chief Commercial Officer
Mr. Ankur Dhingra
(49)Chief Financial Officer
Dr. Steven Barnard
(64)Chief Technology Officer
Mr. Kevin Pegels
(57)Chief of Global Operations
Illumina Supply Chain
Frequently asked questions about Illumina
The business model of Illumina Inc focuses on developing and selling genetic sequencing and array-based solutions. Illumina specializes in the research, clinical, and applied markets and offers a wide range of products and services. Their innovative technologies enable researchers to sequence DNA, RNA, and whole genomes efficiently and accurately, facilitating various applications in genomics. By providing exceptional sequencing platforms, consumables, and data analysis tools, Illumina aims to empower scientists worldwide to unlock the power of the genome. With a strong commitment to advancing precision medicine, Illumina plays a significant role in catalyzing breakthrough discoveries and contributing to various scientific and medical advancements.
Illumina stock
Illumina Peer Group
Illumina Ticker
Illumina FIGI
All fundamentals and in-depth analysis of Illumina
Our stock analysis for Illumina Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Illumina Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.